<SEC-DOCUMENT>0001474506-24-000256.txt : 20241122
<SEC-HEADER>0001474506-24-000256.hdr.sgml : 20241122
<ACCEPTANCE-DATETIME>20241122160918
ACCESSION NUMBER:		0001474506-24-000256
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240816
FILED AS OF DATE:		20241122
DATE AS OF CHANGE:		20241122

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			BALLANTYNE JOHN
		CENTRAL INDEX KEY:			0001701346
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41141
		FILM NUMBER:		241489818

	MAIL ADDRESS:	
		STREET 1:		7410 CLAIRE DRIVE SOUTH,
		CITY:			FARGO,
		STATE:			ND
		ZIP:			58104

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Glucotrack, Inc.
		CENTRAL INDEX KEY:			0001506983
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				980668934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070
		BUSINESS PHONE:		972 (8) 675-7878

	MAIL ADDRESS:	
		STREET 1:		301 RT 17 NORTH
		STREET 2:		SUITE 800
		CITY:			RUTHERFORD
		STATE:			NJ
		ZIP:			07070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GlucoTrack, Inc.
		DATE OF NAME CHANGE:	20220328

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integrity Applications, Inc.
		DATE OF NAME CHANGE:	20101203
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2024-08-16</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001506983</issuerCik>
        <issuerName>Glucotrack, Inc.</issuerName>
        <issuerTradingSymbol>GCTK</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001701346</rptOwnerCik>
            <rptOwnerName>BALLANTYNE JOHN</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>301 ROUTE 17 NORTH, SUITE 800</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>RUTHERFORD</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07070</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1020033</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Ballantyne Revocable Living Trust</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These shares are directly owned by the John A. Ballantyne Revocable Living Trust dated 08/01/2017 (the &quot;Ballantyne Revocable Living Trust&quot;). The reporting person has voting and investment control over the shares of common stock held by the Ballantyne Revocable Living Trust. The reporting person disclaims beneficial ownership of the shares of common stock held by the Ballantyne Revocable Living Trust except to the extent of his pecuniary interest therein.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Nelson Mullins Riley &amp; Scarborough LLP, Attorney-in-Fact</signatureName>
        <signatureDate>2024-11-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>jballantynepoa.txt
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
POWER OF ATTORNEY

Known all by these presents, that the undersigned hereby constitutes and
appoints each of David Mannheim, Esq., Kathryn Simons, Esq., Joy Zheng, Esq.,
or any other representatives of Nelson Mullins Riley & Scarborough, LLP,
and each of them acting alone, signing singly, the undersigned's true and
lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer, director, or 10% or more stockholder, as applicable,
of Glucotrack, Inc. (the "Company"), Forms ID Application
in order to obtain EDGAR filing codes, 3, 4, 5, Update Passphrase
Acknowledgment (and any amendments thereto) in accordance with
Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"1934 Act") and Schedule 13D and/or Schedule 13G (and any amendment
thereto) in accordance with the 1934 Act, and the rules promulgated thereunder;

(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute
any such Application on Form ID, 3, 4, 5, Update Passphrase Acknowledgment
and Schedule 13D and/or Schedule 13G (and any amendments thereto) and to
file timely such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with
the foregoing which in the opinion of such attorney-in-fact may be
of benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and
powers herein granted, as fully to all intents and purposes as the undersigned
might or could do if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact,
or such attorney-in-fact's substitute or substitutes, shall lawfully do or
cause to be done by virtue of this power of attorney and the rights and powers
herein granted. The undersigned acknowledges that the foregoing attorneys-in-
fact, in serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms ID, 3, 4, 5 and Schedule 13D
and Schedule 13G with respect to the undersigned's holdings of and transactions
in securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 20th day of August, 2024.


___/s/ John Ballantyne_____________
John Ballantyne
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
